Peruvoside

Synonyms: Encordin
Peruvoside 是一种有效的 Src、PI3K、JNK、STAT 和 EGFR 抑制剂,可诱导细胞凋亡 (apoptosis) 和自噬 (autophagy),在乳腺癌、肺癌、肝癌和白血病中具有广谱抗肿瘤活性,对正义 RNA 病毒具有广谱、强效的抗病毒活性,并能增加 Gefitinib (MS-R64130) 耐药肿瘤细胞 (A549、PC9/gef 和 H1975) 的敏感性。
产品编号: MS-Z24447 纯度: 99.32% CAS No.: 1182-87-2 分子式: C30H44O9 分子量: 548.66
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Peruvoside 是一种有效的 Src、PI3K、JNK、STAT 和 EGFR 抑制剂,可诱导细胞凋亡 (apoptosis) 和自噬 (autophagy),在乳腺癌、肺癌、肝癌和白血病中具有广谱抗肿瘤活性,对正义 RNA 病毒具有广谱、强效的抗病毒活性,并能增加 Gefitinib (MS-R64130) 耐药肿瘤细胞 (A549、PC9/gef 和 H1975) 的敏感性。

生物实验数据

生物活性 Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR that induces apoptosis and autophagy, exhibits broad-spectrum antitumor activity in breast cancer, lung cancer, liver cancer, and leukemia, displays broad-spectrum and potent antiviral activity against positive-sense RNA viruses, and increases the sensitivity of Gefitinib (MS-R64130)-resistant tumor cells (A549, PC9/gef, and H1975).
体外研究
(In Vitro)

Peruvoside (50-5000 nM,24 小时) 抑制了 PC9,PC9/gef,H3255,和 H1975 细胞系的活力和增殖。
Peruvoside (0.005-0.5 μM, 72 小时) 与 Gefitinib (0.01~0.5 μM) 联用时,增强了 A549, PC9/gef 和 H1975 细胞对 Gefitinib 的敏感程度。
Peruvoside (0-100 μM,24 小时) 诱导 MCF-7,HpG2 和 A549 细胞的周期停滞和凋亡[2。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Peruvoside 相关抗体:

Cell Proliferation Assay

Cell Line: PC9, PC9/gef, H3255, and H1975 cell lines
Concentration: 0, 0.01, 0.05, 0.1, 0.5, 1 μM
Incubation Time: 24, 48, 72, 96 h.
Result: Inhibited the viabilities of TKI-sensitive and TKI-resistant cell lines at all tested time points.
Inhibited the EGFR-mutant lung cancer cell viability and proliferation with 24 h IC50s of 48 nM, 74 nM, 67 nM, 143 nM, 277 nM and 428 nM for A549, PC9, PC9/gef, H3255, H1975 and BEAS-2B cells, respectively.
Significantly inhibited the proliferation of A549 (48, 72, and 96 h) and H3255 (24, 48, 72, and 96 h) lungcancer cells.

Cell Viability Assay

Cell Line: A549, PC9/gef and H1975 cell lines
Concentration: 0.005, 0.0075, 0.01, 0.025, 0.05, 0.5 μM (in combination with 0.01, 0.05, 0.1, 0.25, 0.5 μM Gefitinib)
Incubation Time: 72 h.
Result: Had synergistic effects on A549 cells at the combination of 0.005, 0.075, or 0.01 μM and a low dose of gefitinib (0.01 or 0.05 μM).
Increased the sensitivity of PC9/gef and H1975 cells to Gefitinib at 0.025 or 0.05 μM.

Apoptosis Analysis

Cell Line: MCF-7, A549 and HepG2 cell lines
Concentration: 0-100 μM
Incubation Time: 24 h
Result: Induced cell cycle arrest and apoptosis with lethal concentrations of IC50 for (MCF-7 - 100 nM), (A549 – 100 nM) and (HepG2 - 100 nM), respec-tively.
Arrested cell cycle at G0/G1 in MCF-7, A549 and HepG2 cells.
Significantly decreased the transcription of Chk1, Chk2, CDK6 and Cyclin D1 cell cycle genes in MCF-7, A549, and HepG2 cells.
体内研究
(In Vivo)

Peruvoside (0.1 mg/kg,腹腔注射;一天一次,连续 28 天) 抑制肺癌小鼠模型的肿瘤生长。
Peruvoside (0.59 mg/kg,腹腔注射;一天一次,连续 7 天) 降低了 EV-A71 感染小鼠模型的死亡率。

Animal Model: Lung cancer mouse model
Dosage: 0.1 mg/kg
Administration: Intraperitoneal injection (i.p.); Once daily for 28 days
Result: Reduced the tumour size to 129.9 mm3, which was significantly smaller than the control group (348 mm3).
Significantly decreased levels of phosphorylated Src Y419 in tumour tissues compared with control tissues.
Animal Model: EV-A71-infected mice model
Dosage: 0.59 mg/kg
Administration: Intraperitoneal injection (i.p.); Once daily for 7 days
Result: Substantially reduced clinical scores based on physical symptoms of body weight, activity,breathing, movement, and dehydration.
Showed about 6 log reduction in viral titre with 99.9% efficacy in inhibiting virus.
性状 固体
颜色 White to off-white

化学信息

分子量 548.66
分子式 C30H44O9
CAS No. 1182-87-2
别名 Encordin

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 250 mg/mL (455.66 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8226 mL9.1131 mL18.2262 mL45.5656 mL
5 mM0.3645 mL1.8226 mL3.6452 mL9.1131 mL
10 mM0.1823 mL0.9113 mL1.8226 mL4.5566 mL
15 mM0.1215 mL0.6075 mL1.2151 mL3.0377 mL
20 mM0.0911 mL0.4557 mL0.9113 mL2.2783 mL
25 mM0.0729 mL0.3645 mL0.7290 mL1.8226 mL
30 mM0.0608 mL0.3038 mL0.6075 mL1.5189 mL
40 mM0.0456 mL0.2278 mL0.4557 mL1.1391 mL
50 mM0.0365 mL0.1823 mL0.3645 mL0.9113 mL
60 mM0.0304 mL0.1519 mL0.3038 mL0.7594 mL
80 mM0.0228 mL0.1139 mL0.2278 mL0.5696 mL
100 mM0.0182 mL0.0911 mL0.1823 mL0.4557 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础